TABLE 1.

Reported reduction in NfL levels after treatment with DMTs.

DMTs	Reduction at last follow up
Natalizumab	37%, p = 0.03 (Christensen et al., 2014)
	20%, p < 0.001 (Kapoor et al., 2018)
	30%, p < 0.001 (Gunnarsson et al., 2011)
Fingolimod vs IFNβ1a	38%, p < 0.001 (Kuhle et al., 2019a)
Alemtuzumab and disease activity	DMT associated with no disease activity p < 0.001 (Hyun et al., 2020)
IFN or glatiramer acetate to rituximab	21%, p = 0.01 (de Flon et al., 2016)
Injectable therapies to fingolimod	33%, p < 0.001 (Piehl et al., 2018)
Ocrelizumab vs placebo	43%, p < 0.001 (Bar -Or et al., 2019)
Ibudilast vs placebo	no difference (Fox et al., 2021)